The UK Court of Appeals upheld the validity of Moderna’s key EP’949 patent covering modified mRNA technology used in COVID-19 vaccines, ruling that Pfizer/BioNTech’s Comirnaty vaccine infringes on Moderna’s intellectual property. The decision affirms earlier rulings and supports Moderna’s global enforcement efforts to protect its mRNA platform, which is central to its vaccine development and competitive positioning in the market.